Zhejiang AngLiKang PharmaceuticalLTD Past Earnings Performance
Past criteria checks 4/6
Zhejiang AngLiKang PharmaceuticalLTD has been growing earnings at an average annual rate of 5.9%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been growing at an average rate of 4.8% per year. Zhejiang AngLiKang PharmaceuticalLTD's return on equity is 9.6%, and it has net margins of 8.9%.
Key information
5.9%
Earnings growth rate
0.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 4.8% |
| Return on equity | 9.6% |
| Net Margin | 8.9% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Zhejiang AngLiKang PharmaceuticalLTD makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 1,708 | 152 | 575 | 127 |
| 31 Mar 23 | 1,655 | 135 | 619 | 119 |
| 31 Dec 22 | 1,568 | 127 | 633 | 113 |
| 30 Sep 22 | 1,457 | 153 | 641 | 83 |
| 30 Jun 22 | 1,450 | 133 | 638 | 69 |
| 31 Mar 22 | 1,400 | 126 | 660 | 56 |
| 01 Jan 22 | 1,380 | 120 | 674 | 53 |
| 30 Sep 21 | 1,358 | 115 | 643 | 52 |
| 30 Jun 21 | 1,315 | 144 | 678 | 49 |
| 31 Mar 21 | 1,303 | 155 | 696 | 45 |
| 31 Dec 20 | 1,290 | 164 | 748 | 44 |
| 30 Sep 20 | 1,247 | 146 | 781 | 49 |
| 30 Jun 20 | 1,256 | 132 | 804 | 45 |
| 31 Mar 20 | 1,319 | 120 | 837 | 42 |
| 31 Dec 19 | 1,396 | 112 | 828 | 37 |
| 30 Sep 19 | 1,437 | 100 | 835 | 40 |
| 30 Jun 19 | 1,389 | 89 | 809 | 45 |
| 31 Mar 19 | 1,371 | 109 | 747 | 47 |
| 31 Dec 18 | 1,255 | 109 | 687 | 46 |
| 30 Sep 18 | 1,167 | 122 | 652 | 44 |
| 31 Dec 17 | 873 | 101 | 285 | 41 |
| 31 Dec 16 | 672 | 82 | 105 | 0 |
| 31 Dec 15 | 774 | 64 | 95 | 0 |
| 31 Dec 14 | 682 | 50 | 87 | 0 |
Quality Earnings: 002940 has high quality earnings.
Growing Profit Margin: 002940's current net profit margins (8.9%) are lower than last year (9.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002940's earnings have grown by 5.9% per year over the past 5 years.
Accelerating Growth: 002940's earnings growth over the past year (14.3%) exceeds its 5-year average (5.9% per year).
Earnings vs Industry: 002940 earnings growth over the past year (14.3%) exceeded the Pharmaceuticals industry -1.5%.
Return on Equity
High ROE: 002940's Return on Equity (9.6%) is considered low.